LivaNova (NASDAQ:LIVN) Shares Pass Below Fifty Day Moving Average – Here’s What Happened

Shares of LivaNova PLC (NASDAQ:LIVN) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $48.71 and traded as low as $47.60. LivaNova shares last traded at $47.82, with a volume of 562,307 shares trading hands.

Analysts Set New Price Targets

LIVN has been the subject of several analyst reports. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Tuesday, January 28th. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 23rd. Mizuho dropped their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Finally, Robert W. Baird boosted their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Stock Down 0.3 %

The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a market capitalization of $2.60 billion, a P/E ratio of 113.86 and a beta of 1.00. The firm’s fifty day moving average price is $48.71 and its 200-day moving average price is $49.81.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by insiders.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the business. Central Pacific Bank Trust Division boosted its holdings in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of LivaNova during the 3rd quarter worth $217,000. Inceptionr LLC bought a new stake in shares of LivaNova during the 4th quarter worth $217,000. Sanctuary Advisors LLC acquired a new position in shares of LivaNova in the 3rd quarter worth $219,000. Finally, Edgestream Partners L.P. acquired a new stake in shares of LivaNova during the third quarter worth $244,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.